证券代码：688068 证券简称：热景生物 公告编号：2025-016 北京热景生物技术股份有限公司 2025 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 3 月 6 日 （二） 股东大会召开的地点：北京市大兴区中关村科技园区大兴生物医药产业 基地庆丰西路 55 号公司三层会议室 是 （五） 公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 （一） 非累积投票议案 1、 议案名称：关于增加公司经营范围暨修订《公司章程》并办理工商变更登记 的议案 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 109 | | --- | --- | | 普通股股东人数 | 109 | | 2、出席会议的股东所持有的表决权数量 | 41,870,531 | | 普通股股东所持有表决权数量 | 41,87 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.: 010-50867666 传真/Fax: 010-56916450 网址/Website: www.kangdalawyers.com 北京市康达律师事务所 关于北京热景生物技术股份有限公司 2025 年第一次临时股东大会的 法律意见书 康达股会字【2025】第 0046 号 二〇二五年三月 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以下简称"《规则》"）、《北 京热景生物技术股份有限公司章程》（以下简称"《公司章程》"）及北京热景生物技术 股份有限公司（以下简称"公司"）与北京市康达律师事务所（以下简称"本所"）签 订的法律顾问协议，本所律师对公司 2025 年第一次临时股东大会（以下简称"本次 会议"或"本次股东大会"）进行见证并出 ...

Summary of the Conference Call for 热景生物 (Rejane Biotech) Company Overview - 热景生物 is transitioning from its core IVD (In Vitro Diagnostics) business to the innovative drug sector through its subsidiaries: 顺景医药, 窑井基因, and 于景药业, focusing on areas such as cardiac-targeted small nucleic acid technology, small nucleic acid drugs, and gastrointestinal probiotics [2][3][6] Core Products and Innovations - The core product SGC001 monoclonal antibody targets acute myocardial infarction (AMI) by inhibiting the inflammatory response mediated by S100A8/A9 proteins, potentially delaying myocardial cell death and improving patient outcomes, especially significant given over 1 million AMI cases annually in China [2][7][11] - SGC001 is designed for early administration during AMI, filling a treatment gap between onset and PCI (Percutaneous Coronary Intervention), aiming to control inflammation and reduce complications [2][12][13] - The company is also developing other innovative drugs, including dual-antibody ADCs, expected to enter clinical trials by 2025 [3] Early Screening and Detection - 热景生物 is actively developing microRNA test kits for early cancer screening, including for pancreatic, gastric, liver, urinary tract, and prostate cancers, with the 小薇安 kit for liver cancer achieving world-leading sensitivity and specificity [4][5] - The integration of AI diagnostic technology enhances the accuracy of liver cancer risk prediction models, potentially increasing market acceptance [4] Financial Performance and Market Potential - Since its establishment in 2005 and listing on the Sci-Tech Innovation Board in 2019, 热景生物 has shown steady performance and is currently in a rapid transformation phase, focusing on innovative drug development [6][24] - The market potential for its drugs is substantial, with estimates suggesting a domestic market size of 5-6 billion RMB and a potential overseas market reaching 10 billion USD [4][22][23] Clinical Trials and Research Collaborations - Ongoing clinical trials for SGC001 involve ST-segment elevation AMI patients, with safety and preliminary efficacy being key observation metrics [21] - Collaborations with renowned institutions, such as 安贞医院, enhance research capabilities and accelerate the clinical translation of new diagnostic markers and therapeutic targets [8][9] Unique Drug Design Features - The drug design features a short half-life, aligning with the biological characteristics of S100A8/A9, and preclinical studies using rhesus monkey models have shown promising results in reducing myocardial infarction area and improving sequential scores [20] Management Team - The management team, led by Chairman 林长青 and Chief Scientist 孙志伟, has a strong scientific background and has successfully guided the company through its transition to innovative pharmaceuticals [10] Conclusion - 热景生物 is positioned for significant growth in the innovative drug market, with a strong pipeline of products and a focus on addressing critical healthcare needs, particularly in the treatment of acute myocardial infarction and cancer detection [24]

Investment Rating - The report assigns an "Accumulate" rating for the company, indicating a positive outlook based on its innovative pipeline and potential in the heart failure market [5][65]. Core Insights - The company has a rich pipeline of innovative drugs, particularly the SGC001 antibody for acute myocardial infarction, which is expected to fill a significant clinical gap and has substantial domestic and international market potential [6][49]. - The company is actively expanding its innovative pipeline through subsidiaries focusing on nucleic acid drugs, antibody drugs, and probiotics, which are in various stages of development [7][20]. - The company has established itself as a leading brand in POCT (Point of Care Testing) and is integrating diagnostic and therapeutic strategies, particularly in the field of acute myocardial infarction [7][18]. Summary by Sections Market Performance - As of February 28, 2025, the closing price is 67.30 CNY, with a total market capitalization of 6,223.55 million CNY [3]. Financial Forecast - The company is projected to generate total revenues of 5.11 billion CNY in 2024, 6.02 billion CNY in 2025, and 7.08 billion CNY in 2026, with year-on-year growth rates of -5.61%, 17.85%, and 17.55% respectively [8][63]. - The net profit attributable to the parent company is expected to be -1.77 billion CNY in 2024, -0.68 billion CNY in 2025, and 0.43 billion CNY in 2026 [8][65]. Business Strategy - The company is leveraging its expertise in POCT to explore innovative drug development, establishing a multi-omics diagnostic technology platform and expanding into antibody and exosome drug fields [18][19]. - The SGC001 drug, developed for acute myocardial infarction, has received dual approval for clinical trials in both the US and China, highlighting its potential as a first-in-class treatment [48][49]. Competitive Position - The company is compared with peers in the POCT sector, such as Wanfu Biology and Jiuan Medical, indicating a stable POCT business and promising growth in innovative drug development [8][65].

证券代码：688068 证券简称：热景生物 北京热景生物技术股份有限公司 2025 年第一次临时股东大会会议资料 北京热景生物技术股份有限公司 2025 年第一次临时股东大会会议资料 2025 年 2 月 | 2025 | 年第一次临时股东大会会议须知 | 2 | | --- | --- | --- | | 2025 | 年第一次临时股东大会会议议程 | 4 | | 2025 | 年第一次临时股东大会会议议案 | 6 | 北京热景生物技术股份有限公司 2025 年第一次临时股东大会会议资料 北京热景生物技术股份有限公司 2025 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会 的顺利进行，根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市 公司股东大会规则》以及《北京热景生物技术股份有限公司章程》、《北京热景生物 技术股份有限公司股东大会议事规则》等相关规定，北京热景生物技术股份有限公司 （以下简称"公司"）特制定本次股东大会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作人员 将对出席会议者的身份进行必要的核对工 ...

Financial Performance - The total operating revenue for 2024 was 51,089.06 million CNY, a decrease of 7.62% compared to the previous year[4] - The net profit attributable to the parent company was -17,923.07 million CNY, a decline of 728.52% year-on-year[4] - The basic earnings per share fell by 725.81% to -1.94 CNY[5] - The company experienced a 317.82% increase in net profit attributable to the parent company after excluding non-recurring gains and losses, totaling -24,315.82 million CNY[4] - The weighted average return on equity decreased by 6.55 percentage points to -5.70%[5] Assets and Equity - The total assets at the end of the reporting period were 330,909.69 million CNY, down 7.35% from the previous year[5] - The equity attributable to the parent company decreased by 8.49% to 308,144.19 million CNY[5] Research and Development - The R&D investment for 2024 reached 11,276.71 million CNY, accounting for 22.07% of the operating revenue[7] - The company reported an investment loss of 4,763.16 million CNY from joint ventures due to increased R&D expenditures[7] Impairment and Competition - A total of 8,478.31 million CNY was recognized as impairment losses on operating assets due to intensified industry competition[7]

Core Viewpoint - The company reported a decline in revenue and a significant net loss for the year 2024, indicating challenges in its financial performance [1] Financial Performance - The total operating revenue for 2024 was 511 million yuan, representing a year-on-year decrease of 7.62% [1] - The net profit for the year was a loss of 179 million yuan, compared to a net profit of 28.52 million yuan in the same period last year [1] Research and Development - The company continued to invest in research and development for clinical immunodiagnostics and molecular diagnostics technology platforms [1] - The total R&D expenditure amounted to 113 million yuan, accounting for 22.07% of the operating revenue [1]

一、获得资质的具体情况 （一） 获得境外认证情况 | 序号 | 产品中文名称 | 产品英文名称 | 注册证号 | 分类 | 获批日期 | 有效期至 | 发证 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | （备案号） | | | | 国家 | | 1 | 糖化血红蛋白 测定试剂盒(磁 | Glycosylated Hemoglobin Chemiluminescence | / | / | 2025/3/1 | 2026/3/1 | IFCC (Internationa l Federation | | | | | | | | | of Clinical | | | 微粒化学发光 | Immunoassay Kit | | | | | Chemistry | | | 免疫分析法) | | | | | | and | | | | (CLIA) | | | | | Laboratory | | | | | | | | | Medicine ) | | 2 | 蛋白提取试剂 | Protein Extraction Kit | DE/CA22/ ...

证券代码：688068 证券简称：热景生物 公告编号：2025-013 北京热景生物技术股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/11/15 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 11 月 日~2025 年 | 15 | 2 | 月 14 | 日 | | 预计回购金额 | 万元 5,800 万元~10,000 | | | | | | 回购价格上限 | 元/股 82.69 | | | | | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | √为维护公司价值及股东权益 | | | | | | 实际回购股数 | 股 981,119 | | | | | | 实际回购股数占总股本比例 | 1.06% | | | | | | 实际回购金额 | 元 71,422,052 ...

北京热景生物技术股份有限公司 章 程 2025 年 2 月修订 1 | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 5 | | | 第一节 股份发行 5 | | | 第二节 股份增减和回购 6 | | | 第三节 股份转让 7 | | 第四章 | 股东和股东大会 8 | | | 第一节 股东 8 | | | 第二节 股东大会的一般规定 11 | | | 第三节 股东大会的召集 15 | | | 第四节 股东大会的提案与通知 17 | | | 第五节 股东大会的召开 18 | | | 第六节 股东大会的表决和决议 21 | | 第五章 | 董事会 26 | | | 第一节 董事 26 | | | 第二节 董事会 30 | | | 第三节 董事会专门委员会 35 | | 第六章 | 总经理及其他高级管理人员 37 | | 第七章 | 监事会 39 | | | 第一节 监事 39 | | | 第二节 监事会 39 | | 第八章 | 财务会计制度、利润分配和审计 41 | | | 第一节 财务会计制度 41 | | | 第二节 内部审计 46 ...